Compare Ginkgo Bioworks Holdings Inc (DNA) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Alphabet Inc Class A — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.18 (market cap $763.64M), while Alphabet Inc Class A trades at $354.14 (market cap $4.24T). The key difference: Alphabet Inc Class A is far larger — about 5552.4× Ginkgo Bioworks Holdings Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Alphabet Inc Class A for 85 Days on average.
| DNA | GOOGL | |
|---|---|---|
Market Cap | $763.64M | $4.24T |
Volume | 3,204,177 | 23,392,850 |
Sector | Health | Media |
52-Week High | $15.83 | $402.62 |
52-Week Low | $5.48 | $236.59 |
Typical Hold Time | 7 Days | 85 Days |
Enterprise Value | $865.59M | $4.13T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Alphabet (GOOGL) trades at $353.47, up 0.85% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Technical indicators signal bullish momentum with the current price above key support levels. Recent earnings beats and strong analyst consensus support continued upside potential.
Outlook remains positive with 87% analyst buy ratings and $431.83 price target representing 22% upside. Key risks include antitrust scrutiny and AI competition, but Alphabet's diversified revenue streams and strong cash flow position the company for sustained growth. The combination of technical strength and fundamental excellence suggests favorable risk-reward for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
